{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:07:39Z","timestamp":1794557259539,"version":"4.9.1"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Standard-of-care therapy for IgA nephropathy has historically relied on renin\u2013angiotensin\u2013aldosterone system inhibitors.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Current treatment goals aim to slow eGFR decline to reduce the risk of ESKD.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Analysis of renin\u2013angiotensin\u2013aldosterone system inhibitor therapy alone found an eGFR decline of \u22124.5 ml\/min per 1.73 m\n                            <jats:sup>2<\/jats:sup>\n                            per year, which may not limit ESKD risk.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      IgA nephropathy is a chronic autoimmune kidney disease characterized by deposition of immune complexes in the glomeruli, leading to inflammation and progressive, irreversible, kidney damage. Patients with IgA nephropathy face a lifetime risk of ESKD, and an associated increase in mortality unless their annual eGFR decline is generally maintained at or below 1 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      . The current standard of care in IgA nephropathy involves supportive CKD therapies, notably renin\u2013angiotensin\u2013aldosterone system inhibitors (RAASi). Importantly, the long-term effectiveness of RAASi in slowing IgA nephropathy disease progression remains uncertain. Meta-analyses of randomized controlled trials with comparable designs offer an opportunity to assess the impact of RAASi therapy on kidney function. Such analyses facilitate outcome comparisons across studies and may generate important evidence and contribute to informed clinical decision making.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A meta-analysis was conducted using randomized controlled trials that reported the slope of eGFR decline and included one arm receiving maximally tolerated doses of RAASi. The analysis aimed to evaluate the impact of RAASi therapy on kidney function in high-risk patients with IgA nephropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A systematic literature review of four databases returned 171 studies published between January 2006 and November 2024. Of these, ten included a control arm of participants with IgA nephropathy receiving maximized RAASi treatment (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      =1366) and reported eGFR annualized slope decline. Meta-analysis of the pooled data demonstrated a mean annual eGFR slope decline of \u22124.5 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      (95% confidence interval, \u22125.3 to \u22123.8) among participants treated with RAASi therapy alone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment with maximally tolerated RAASi alone does not sufficiently slow the rate of eGFR decline in high-risk patients with IgA nephropathy, leaving patients at risk of ESKD. These findings underscore the need for disease-modifying therapies capable of effectively preserving kidney function, particularly in this predominantly young patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.0000001130","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:00:46Z","timestamp":1786550446000},"page":"1701-1709","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The Impact of Renin\u2013Angiotensin\u2013Aldosterone System Inhibitors in IgA Nephropathy"],"prefix":"10.2215","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8117-6010","authenticated-orcid":false,"given":"Anjay","family":"Rastogi","sequence":"first","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-9415","authenticated-orcid":false,"given":"Mrinalini","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0908-5296","authenticated-orcid":false,"given":"Kosuke","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2627-8957","authenticated-orcid":false,"given":"Gabriel","family":"Munoz","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1386-0619","authenticated-orcid":false,"given":"Lewis","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maham","family":"Khalid","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9703-6469","authenticated-orcid":false,"given":"Connie M.","family":"Rhee","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California"},{"name":"Division of Nephrology, Hypertension, and Kidney Transplantation, University of California, Irvine, Orange, California"},{"name":"Nephrology Section, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"2","key":"B1-20261103","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant."},{"issue":"6","key":"B2-20261103","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"B3-20261103","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol."},{"issue":"2","key":"B4-20261103","doi-asserted-by":"crossref","first-page":"36","DOI":"10.36469\/jheor.2021.26129","article-title":"A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy","volume":"8","author":"Kwon","year":"2021","journal-title":"J Health Econ Outcomes Res."},{"issue":"17","key":"B5-20261103","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.3390\/jcm13175255","article-title":"Pathogenic immunoglobulin A-producing cells in immunoglobulin A nephropathy","volume":"13","author":"Makita","year":"2024","journal-title":"J Clin Med."},{"issue":"3","key":"B6-20261103","doi-asserted-by":"crossref","first-page":"e91756","DOI":"10.1371\/journal.pone.0091756","article-title":"Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan","volume":"9","author":"Moriyama","year":"2014","journal-title":"PLoS One."},{"issue":"10","key":"B7-20261103","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/ndt\/gfad082","article-title":"The incidence and prevalence of IgA nephropathy in Europe","volume":"38","author":"Willey","year":"2023","journal-title":"Nephrol Dial Transplant."},{"issue":"10","key":"B8-20261103","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"B9-20261103","doi-asserted-by":"crossref","first-page":"715253","DOI":"10.3389\/fphar.2021.715253","article-title":"An update on targeted treatment of IgA nephropathy: an autoimmune perspective","volume":"12","author":"Huang","year":"2021","journal-title":"Front Pharmacol."},{"issue":"3-4","key":"B10-20261103","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1359-6101(03)00023-6","article-title":"The TNF family members BAFF and APRIL: the growing complexity","volume":"14","author":"Mackay","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"key":"B11-20261103","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF and APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu Rev Immunol."},{"issue":"4S","key":"B12-20261103","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int."},{"issue":"11","key":"B13-20261103","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/ndt\/gfad146","article-title":"IgA nephropathy in adults-treatment standard","volume":"38","author":"Gleeson","year":"2023","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B14-20261103","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ekir.2024.10.004","article-title":"Study design and baseline characteristics of ALIGN, a randomized controlled study of atrasentan in patients with IgA nephropathy","volume":"10","author":"Heerspink","year":"2025","journal-title":"Kidney Int Rep."},{"issue":"6","key":"B15-20261103","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int."},{"issue":"10405","key":"B16-20261103","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet."},{"issue":"6","key":"B17-20261103","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med."},{"key":"B18-20261103","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"issue":"10084","key":"B19-20261103","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet."},{"issue":"6","key":"B20-20261103","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med."},{"issue":"2","key":"B21-20261103","doi-asserted-by":"crossref","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open."},{"issue":"1","key":"B22-20261103","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.ajkd.2011.09.014","article-title":"Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial","volume":"59","author":"Liu","year":"2012","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B23-20261103","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis."},{"issue":"23","key":"B24-20261103","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med."},{"issue":"1","key":"B25-20261103","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int."},{"issue":"4","key":"B26-20261103","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin J Am Soc Nephrol."},{"issue":"19","key":"B27-20261103","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA."},{"issue":"12","key":"B28-20261103","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B29-20261103","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med."},{"issue":"10417","key":"B30-20261103","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet."},{"issue":"1","key":"B31-20261103","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int."},{"issue":"4","key":"B32-20261103","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int."},{"issue":"1","key":"B33-20261103","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"B34-20261103","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1681\/ASN.2018101017","article-title":"Mortality in IgA nephropathy: a nationwide population-based cohort study","volume":"30","author":"Jarrick","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"B35-20261103","doi-asserted-by":"crossref","first-page":"e51225","DOI":"10.1371\/journal.pone.0051225","article-title":"Mortality of IgA nephropathy patients: a single center experience over 30 years","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One."},{"issue":"4","key":"B36-20261103","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2215\/CJN.07420716","article-title":"IgA nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B37-20261103","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41687-019-0095-4","article-title":"Patient experience after kidney transplant: a conceptual framework of treatment burden","volume":"3","author":"Lorenz","year":"2019","journal-title":"J Patient Rep Outcomes."},{"issue":"5","key":"B38-20261103","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.2215\/CJN.09381010","article-title":"Recurrence of secondary glomerular disease after renal transplantation","volume":"6","author":"Ponticelli","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9","key":"B39-20261103","doi-asserted-by":"crossref","first-page":"100693","DOI":"10.1016\/j.xkme.2023.100693","article-title":"Impact of proteinuria and kidney function decline on health care costs and resource utilization in adults with IgA nephropathy in the United States: a retrospective analysis","volume":"5","author":"Lerma","year":"2023","journal-title":"Kidney Med."},{"issue":"12","key":"B40-20261103","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B41-20261103","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1681\/ASN.2011111112","article-title":"Corticosteroid therapy in IgA nephropathy","volume":"23","author":"Lv","year":"2012","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B42-20261103","doi-asserted-by":"crossref","first-page":"151573","DOI":"10.1016\/j.semnephrol.2025.151573","article-title":"The rapidly changing treatment landscape of IgA nephropathy","volume":"44","author":"Cheung","year":"2024","journal-title":"Semin Nephrol."},{"issue":"4","key":"B43-20261103","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5301\/jn.5000218","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J Nephrol."},{"issue":"11","key":"B44-20261103","doi-asserted-by":"crossref","first-page":"e3099","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine (Baltimore)."},{"issue":"4","key":"B45-20261103","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.0000000541","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy","volume":"36","author":"Barratt","year":"2025","journal-title":"J Am Soc Nephrol."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:00:32Z","timestamp":1793728832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001130"}},"subtitle":["A Meta-Analysis of Randomized Controlled Trials"],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000001130","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"2025-07-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}